← Analyst Upside
AU · rank #17 · 2026-10-21
EOLS
NASDAQ · $486M (USD)
SignalBuy1.2strength 1.2 / 10
verdict · PROCEED
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 1.126 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$0.02 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 4 |
| Insider signal (90d) $0 across 0 unique buyers. | -0.206 |
| Analyst upside Consensus target $15.00 | +103.8% |
| Momentum acceleration 3-month minus 12-month momentum. | +20.77% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 4.50 |
| Gross margin TTM | +66.4% |
| 52w high | $9.31 |
| Market cap (USD) | $486M |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Evolus Inc. is a commercial-stage medical aesthetics company that markets neurotoxins (Jeuveau/Nuceiva) and hyaluronic acid dermal fillers (Evolysse/Estyme) directly to cosmetic practitioners.
Rationale
Unanimous earnings revision agreement (100%), a 52.6% Q2 earnings surprise, and raised 2026 revenue guidance validate the >100% analyst price target upside model.
Material risks
- 1Regulatory enforcement from the FDA's October 2026 untitled letter regarding Jeuveau social media promotions could restrict key marketing channels or require costly corrective campaigns.
- 2High debt load of $156.7 million relative to $45.2 million in cash and ongoing net losses exposes the balance sheet if operational cash outflows persist.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 2 of 3 voted to proceed.
OpenAI
Proceed
Claude
Caution
Gemini
Proceed